No Data
Earnings Update: ScPharmaceuticals Inc. (NASDAQ:SCPH) Just Reported And Analysts Are Trimming Their Forecasts
Maxim Group Maintains ScPharmaceuticals(SCPH.US) With Buy Rating, Maintains Target Price $20
Positive Outlook for ScPharmaceuticals: Strategic Growth and Regulatory Milestones Drive Buy Rating
ScPharmaceuticals Third Quarter 2024 Earnings: Misses Expectations
Analysts Conflicted on These Healthcare Names: Alcon (ALC), Innate Pharma SA (OtherIPHYF) and ScPharmaceuticals (SCPH)
ScPharmaceuticals Shares Are Trading Lower After the Company Reported Worse-than-expected Q3 Sales Results.
No Data
No Data
